WALLY STREET

Altair Nanotechnologies Inc., (ALTI) Inc.engages in developing and commercializing nanomaterial and titanium dioxide pigment technologies in the United States and Canada. The company operates in three divisions: Power and Energy Group, Performance Materials, and Life Sciences. The Power and Energy Group engages in the design, development, and production of nano lithium titanate battery cells, batteries, and battery packs. It also offers related design and test services. In addition, this division involves in the development, production, and sale of products that test electrode materials for use in nano lithium titanate batteries. The Performance Materials division engages in the development and production of titanium dioxide pigment for use in paint and coatings; and nano titanium dioxide materials for use in various applications, including those related to removing contaminants from air and water. This division also involves in the testing, development, marketing, and/or licensing of nano-structured ceramic powders for use in various applications, such as advanced performance coatings, air and water purification systems, and nano-sensor applications. The Life Sciences division engages in the co-development of RenaZorb, a test-stage active pharmaceutical ingredient, which is designed to be useful in the treatment of elevated serum phosphate levels in human patients undergoing kidney dialysis. This division also involves in the development of a manufacturing process related to a test-stage active pharmaceutical ingredient, designed to be useful in the treatment of companion animals. Altair Nanotechnologies, Inc. also provides contract research services to develop intellectual property and/or new products and technology. The company was formerly known as Altair International Inc. and changed its name to Altair Nanotechnologies, Inc. in July 2002. Altair Nanotechnologies, Inc. was founded in 1973 and is headquartered in Reno, Nevada.

Antigenics Inc.,(AGEN) a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases, primarily based on immunological approaches. Its products include Oncophage (vitespen), a patient-specific therapeutic cancer vaccine registered for use in the Russia Federation, as well as under review by the European Medicines Agency for the treatment of kidney cancer patients with earlier-stage disease. The company tested Oncophage in phase 3 clinical trials for the treatment of renal cell carcinoma and metastatic melanoma; and phase 1 and phase 2 clinical trials for various indications, as well as in phase 2 clinical trial for the treatment of recurrent glioma, a type of brain cancer. Its product candidate portfolio also includes QS-21 Stimulon adjuvant, which is used in various vaccines under development in trials for diseases, such as hepatitis, human immunodeficiency virus, influenza, cancer, Alzheimer’s disease, malaria, and tuberculosis; AG-707, a therapeutic vaccine program for the treatment of genital herpes; and Aroplatin, a liposomal chemotherapeutic for the treatment of solid malignancies and B-cell lymphomas. The company was formerly known as Antigenics L.L.C. and changed its name to Antigenics, Inc. in February 2000. Antigenics was founded in 1994 and is headquartered in Lexington, Massachusetts

American International Group, Inc., (AIG) through its subsidiaries, provides insurance and financial services in the United States and internationally. It operates in four segments: General Insurance, Life Insurance and Retirement Services, Financial Services, and Asset Management. The General Insurance segment underwrites various business insurance products, including large commercial or industrial property insurance, excess liability, inland marine, environmental, workers’ compensation, and excess and umbrella coverages. It also offers various specialized forms of insurance, such as aviation, accident and health, equipment breakdown, directors and officers liability, difference-in-conditions, kidnap-ransom, export credit and political risk, and professional errors and omissions coverages. In addition, this segment provides property and casualty reinsurance products to insurers; automobile insurance products; residential mortgage guaranty insurance products; and commercial and consumer lines of insurance products. The Life Insurance and Retirement Services segment offers individual and group life, payout annuities, endowment, and accident and health policies, as well as retirement savings products consisting of fixed and variable annuities. The Financial Services segment provides commercial aircraft and equipment leasing, capital market operations, consumer finance, and insurance premium financing. The Asset Management segment offers investment-related services and investment products to individuals, pension funds, and institutions. The company was founded in 1967 and is based in New York, New York.

Human Genome Sciences, Inc. (HGSI) operates as a biopharmaceutical company in the United States. The company’s clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, and cancer. It focuses on the commercialization of Albuferon (albinterferon alfa-2b) for hepatitis C and LymphoStat-B (belimumab) for lupus. The company has completed Phase III development trials for Albuferon and is conducting two Phase III clinical trials of LymphoStat-B. It also delivers doses of ABthrax (raxibacumab) to the U.S. Strategic National Stockpile for use in the event of an emergency for the treatment of inhalation anthrax. In addition, the company has various drugs in the earlier stages of clinical development for the treatment of cancer, led by the TRAIL receptor antibody HGS-ETR1 and a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins. Further, Human Genome Sciences, Inc., through a strategic collaboration agreement with GlaxoSmithKline, has substantial financial rights to certain products in the GlaxoSmithKline clinical pipeline, including darapladib that is in Phase III development as a treatment for coronary heart disease; and Syncria (albiglutide), which is in Phase III development as a treatment for type 2 diabetes. Additionally, it has a strategic commercial collaboration agreement with Novartis International Pharmaceutical, Ltd. for the co-development and commercialization of Albuferon; and a strategic licensing and collaboration agreement with Aegera Therapeutics, Inc. to develop and commercialize HGS1029 and other small-molecule inhibitors of IAP (inhibitor of apoptosis) proteins in oncology. Human Genome Sciences, Inc. was founded in 1992 and is headquartered in Rockville, Maryland.

GeoMet, Inc., (GMET) an independent energy company, engages in the exploration for, and development and production of natural gas from coal seams and non-conventional shallow gas. Its principal operations and producing properties are located in the Cahaba Basin in Alabama, the central Appalachian Basin in West Virginia, and Virginia, as well as in British Columbia, Canada. As of December 31, 2008, the company controlled a total of approximately 213,000 net acres of coalbed methane, and oil and natural gas development rights. GeoMet also had 320 billion cubic feet of estimated proved reserves. The company was founded in 1985 and is headquartered in Houston, Texas.

Dendreon Corporation, (DNDN) a biotechnology company, engages in the discovery, development, and commercialization of therapeutics to enhance cancer treatment options for patients. The company�s product portfolio includes active cellular immunotherapy, monoclonal antibody, and small molecule product candidates to treat various cancers. Its product candidates comprise Provenge (sipuleucel-T), an active cellular immunotherapy that has completed two Phase III trials for the treatment of asymptomatic, metastatic, and androgen-independent prostate cancer; and Neuvenge (lapuleucel-T), an investigational active immunotherapy for the treatment of patients with breast, ovarian, and other solid tumors expressing HER2/neu. The company also has a range of products in preclinical studies, which include CEA for the treatment of breast, lung, and colon cancer; CA-9 (MN) for the treatment of kidney, colon, and cervical cancer; Anti-Serine Protease for the treatment of multiple cancers; and Anti-HLA-DR for the treatment of hematologic malignancies, as well as TRPM8 for the treatment of lung, breast, prostate, and colon cancer. Dendreon Corporation, formerly known as Activated Cell Therapy, Inc., was founded in 1992 and is headquartered in Seattle, Washington.

E*TRADE Financial Corporation, (ETFC) through its subsidiaries, provides online brokerage and related products and services primarily to individual retail investors, under the brand name of E*TRADE Financial worldwide. It offers various brokerage products and services, including automated order placement and execution of the U.S. and international equities, currencies, futures, options, exchange-traded funds, mutual funds, and bonds. The company also provides quick transfer, wireless account access, extended hours trading, quotes, research, and advanced planning tools. Its banking products and services include checking, savings, sweep, money market, and certificates of deposit products. E*TRADE Financial primarily provides its services through its Web site at etrade.com, as well as through its network of customer service representatives, relationship managers, and investment advisors. The company was founded in 1982 and is based in New York, New York.

Geron Corporation, (GERN)a biopharmaceutical company, develops therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, and diabetes. The company develops a range of anti-cancer therapies, including anti-cancer therapies based on telomerase inhibitors and telomerase therapeutic vaccines, as well as focuses on the development of products using telomerase as a marker for cancer diagnosis, prognosis, patient monitoring, and screening. Its products include GRN163 and GRN163L, which are telomerase inhibitors for the treatment of chronic lymphoproliferative diseases, solid tumors, non-small cell-lung cancer, breast cancer, and multiple myeloma, which are in Phase I trials; and GRNVAC1, a telomerase cancer vaccine that is in Phase II clinical trial for the treatment of acute myelogenous leukemia. Geron Corporation also develops human embryonic stem cell-based therapeutics, with its spinal cord injury treatment. The company has research, development, and commercialization license agreement with Merck & Co., Inc. to use telomerase in non-dendritic cell cancer vaccines; and a license agreement with Sienna Cancer Diagnostics to detect telomerase for in vitro cancer diagnosis. Geron Corporation was founded in 1990 and is based in Menlo Park, California.

Palomar Medical Technologies, Inc., (PMTI) along with its subsidiaries, designs, manufactures, markets, and sells lasers and other light-based products, and related disposable items and accessories for use in medical and cosmetic procedures. It provides a range of products for hair removal; removal of vascular lesions, such as rosacea, spider veins, port wine stains, and hemangiomas; wrinkle reduction; removal of leg veins; removal of benign pigmented lesions, including age and sun spots, freckles, and melasma; tattoo removal; acne treatment; skin resurfacing; pseudofolliculitis barbae treatment; treatment of red pigmentation in hypertrophic and keloid scars; treatment of verrucae, skin tags, and seborrheic keratosis; skin tightening through soft tissue coagulation; scars, including acne scars, stretch marks, and warts; soft tissue coagulation; and various other skin treatments. Palomar Medical offers its products through a network of distributors in Europe, Japan, South and Central America, the Far East, the Middle East, and Australia. The company was founded in 1987 and is headquartered in Burlington, Massachusetts

StemCells, Inc., (STEM) a biopharmaceutical company, engages in the discovery, development, and commercialization of cell-based therapeutics to treat diseases of the central nervous system and liver. The company engages in two product development programs, central nervous system (CNS) Program, which is developing applications for human neural stem cell; and Liver Program, which is developing applications for human liver engrafting cells (hLEC). In its CNS Program, the company completed Phase I clinical trial to evaluate the safety and preliminary efficacy of its HuCNS-SC product candidate (purified human neural stem cells) as a treatment for infantile and late infantile neuronal ceroid lipofuscinosis; and received authorization to initiate a Phase I clinical trial of HuCNS-SC cells as a treatment for Pelizeaus-Merzbacher Disease, a fatal myelination disorder in the brain. Its HuCNS-SC cells are in preclinical development for spinal cord injury and retinal disorders. In Liver Program, the company is in preclinical development and is continuing to improve processes to isolate and purify its hLECs. It has research collaboration agreements with the OHSU Casey Eye Institute to evaluate the company�s HuCNS-SC product candidate as a treatment for retinal degeneration; and Universite Catholique de Louvain (UCL) and the UCL-affiliated Cliniques Universitaires Saint Luc to develop hLEC as a potential cell-based liver therapy. In addition, the company owns cell technologies relating to embryonic stem cells, induced pluripotent stem cells, and tissue-derived (adult) stem cells; infrastructure for providing cell-based assays for drug discovery; the media formulation and reagent business; and an intellectual property portfolio with claims relevant to cell processing, reprogramming, and manipulation, as well as to gene targeting and insertion. The company was founded in 1988 and is based in Palo Alto, California.

Harris & Harris Group, Inc. (TINY) is a venture capital firm specializing in seed, start up, and mid venture investments. It primarily invests in tiny-technology-enabled companies with a focus on nanotechnology, microsystems, and microelectromechanical systems technology. Harris & Harris Group, Inc. was founded in 1981 and is based in New York, New York.